Results 61 to 70 of about 6,404 (193)

Quality of life impact of an adjuvanted recombinant zoster vaccine in adults aged 50 years and older

, 2019
BACKGROUND: To determine the efficacy of an adjuvanted recombinant zoster vaccine in reducing the herpes zoster (HZ) burden of illness, HZ burden of interference with activities of daily living, and HZ impact on quality of life.
Lal, H, Campora, L, Diez-Domingo, J, Korhonen, T, McNeil, S, Andrews, C, Athan, E, Leung, E, Oostvogels, L, Levin, M, Heineman, T, McElhaney, J, Matthews, S, Berglund, J, De Looze, F, Curran, D, Johnson, RW, Volpi, A   +17 more
core   +2 more sources

Vaccination against Herpes zoster in patients with immune-mediated inflammatory rheumatic diseases: new data

Современная ревматология
Patients with immune-mediated inflammatory rheumatic diseases (IIRD) are more likely to develop herpes zoster (HZ) than individuals in the general population.
N. V. Muravyova, B. S. Belov
doaj   +1 more source

Therapeutic Poxviruses Induce the Secretion of Immunostimulating and Anti‐Tumoral Extracellular Vesicles

Journal of Extracellular Vesicles, Volume 15, Issue 6, June 2026.
Immune cells infected by therapeutic poxviruses release increased amounts of extracellular vesicles bearing viral proteins and therapeutic payloads. Such EVs have the ability to activate a CD8+ T‐cell mediated antitumoral immune response and decrease tumor growth.
Lucas Walther, Vincent Mittelheisser, Marie‐Christine Claudepierre, Louis Bochler, Magali Rompais, Jules Deforges, Nathalie Silvestre, Annabel Larnicol, Christine Carapito, Eric Quémeneur, Jacky G Goetz, Karola Rittner, Vincent Hyenne   +12 more
wiley   +1 more source

Recombinant Zoster Vaccination and Risk of Postherpetic Neuralgia or Zoster Ophthalmicus

JAMA Network Open
This cohort study uses health plan data to investigate whether recombinant zoster vaccination is associated with a reduced risk of postherpetic neuralgia or zoster ophthalmicus.
Zerbo, Ousseny, Bartlett, Joan, Fireman, Bruce, Goddard, Kristin, Duffy, Jonathan, Glanz, Jason, Naleway, Allison L., Donahue, James G., Anderson, Tara C., Klein, Nicola P.   +9 more
openaire   +2 more sources

Varicella zoster virus vaccines: an update

ImmunoTargets and Therapy, 2019
Giovanni Gabutti,1 Niccolò Bolognesi,2 Federica Sandri,2 Caterina Florescu,2 Armando Stefanati11Department of Medical Sciences, University of Ferrara, Ferrara, Italy; 2Postgraduate School of Hygiene and Preventive Medicine, University of Ferrara ...
Gabutti G, Bolognesi N, Sandri F, Florescu C, Stefanati A   +4 more
doaj  

Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States

Human Vaccines & Immunotherapeutics
We evaluated the vaccine effectiveness (VE) of two doses of recombinant zoster vaccine (RZV) against herpes zoster (HZ) and postherpetic neuralgia (PHN) in Chinese adults at Kaiser Permanente Southern California (KPSC).
Ana Florea, Lina Sy, Lei Qian, Bradley Ackerson, Yi Luo, Jun Wu, Yanjun Cheng, Jennifer Ku, Leticia Vega Daily, Harpreet Takhar, Jeannie Song, Elizabeth Chmielewski-Yee, O’Mareen Spence, Harry Seifert, Driss Oraichi, Hung Fu Tseng   +15 more
doaj   +1 more source

Knowledge, Attitudes and Practices Survey of Recombinant Zoster Vaccine among Cardiologists and Cardiac Nurses in Italy

Medicina
Background and Objectives: Cardiac patients are particularly at risk of herpes zoster (HZ), which is associated with a higher risk of major cardiovascular events.
Domenico Ponticelli, Ippazio Cosimo Antonazzo, Lorenzo Losa, Anna Zampella, Fabio Di Marino, Gaetano Mottola, Mara Noemi Fede, Fortuna Gallucci, Roberto Magliuolo, Antonio Rainone, Carmine Del Giudice, Antonella Arcari, Pietro Ferrara   +12 more
doaj   +1 more source

Safety of the Zoster Vaccine Recombinant Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center's Experience With 400 Patients

ACR Open Rheumatology, 2020
Objective Patients with rheumatoid arthritis (RA) and other systemic rheumatic diseases (SRDs) are at increased risk of developing herpes zoster (HZ).
Emma Stevens, Michael E. Weinblatt, Elena Massarotti, Frances Griffin, Srinivas Emani, Sonali Desai   +5 more
doaj   +1 more source

Risk of Safety Events in Vitiligo Patients: A Retrospective Real‐World Data Study in the US

The Journal of Dermatology, Volume 53, Issue 5, Page 758-773, May 2026.
ABSTRACT Vitiligo is a chronic autoimmune depigmenting disease characterized by loss of pigment in the skin, hair, or both. As treatment options evolve, particularly with the emergence of oral Janus kinase inhibitors and dual Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor, it is essential to assess ...
Kennedy Cook, Nada M. Elbuluk, Roni Adiri, Alexandre Lejeune, Thomas Edwards, Milena A. Gianfrancesco, Scott P. Kelly, Tatjana Lukic, Edward Nagy, Samantha K. Kurosky, Lynne Napatalung, Iltefat Hamzavi   +11 more
wiley   +1 more source

Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020

, 2023
BackgroundShortly after the launch of a novel adjuvanted recombinant zoster vaccine (RZV), Shingrix, cases of suspected herpes zoster (HZ) or zoster-like skin reactions following immunisation were reported.AimWe aimed to investigate if these skin ...
Keller-Stanislawski, Brigitte, Oberle, Doris, Orru', Stefano, Bierbaum, Sibylle, Huzly, Daniela, Hoffelner, Marcus, Mockenhaupt, Maja, Mahler, Vera, Enk, Alexander Herrmann, Hengel, Hartmut   +9 more
core   +1 more source